NASA’s Former AI Chief Omar Hatamleh Says AGI Is Closer Than We Think, Then Everything Will Change
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
Medtech Insight - February 16, 2026

Aurobindo: Biosimilars Inflection Point Pushed, Pomalidomide Launch Set For Q4
Aurobindo has pushed its projection of an inflection point for biosimilars ahead by a year to FY29 but plans to launch a generic to BMS blockbuster Pomalyst (pomalidomide) in the current quarter. Meanwhile, anti-competitive pricing of penicillin-G by China should now cause less harm.
Generics Bulletin - February 16, 2026

CStone Gets US Clearance For PD-1/VEGF/CTLA-4 Trispecific Study
While Summit/Akeso’s bispecific, ivonescimab, awaits US approval, China’s CStone is moving fast into a broad Phase II study of its trispecific anticancer candidate, with hopes of better safety and efficacy.
Scrip - February 16, 2026

People On The Move: Appointments At Sanofi, Lonza, SkinBioTherapeutics
A round-up of the latest European exec moves: Sanofi hires CEO from Merck; Lonza appoints to its board; SkinBioTherapeutics makes changes as CEO resigns.
HBW Insight - February 16, 2026

US Warning About IND Needed For Omega-3 Study Could Squeeze Supplements’ Preclusion Flexibility
Warning letter, submitted three months after FDA rejected supplement industry groups’ arguments for leeway around how INDs affect dietary ingredient’s availability for use in supplements, stated Prodrome Sciences’ clinical trials with omega-3 supplements should have been registered as IND.
HBW Insight - February 16, 2026

Edwards To Launch Surgical LAAC In 2026 As Structural Heart Expansion Accelerates
Strong full-year 2025 and Q4 sales rise 13% to $1.57bn.
Medtech Insight - February 16, 2026

CBD Used By One In Five Brits, Mostly For Wellbeing, Mental Health And Pain
Nearly one in five UK adults have used CBD in the past year, mainly for wellbeing, mental health and pain, with many users reporting reliance, strong brand?trust considerations and growing concerns about unauthorized products.
HBW Insight - February 16, 2026

How Boehringer Is Breaking Big Pharma Into Biotech-Sized Pieces
Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.
In Vivo - February 16, 2026

Organon Tempers Expectations For Denosumab Biosimilars As Competition Intensifies
Organon says investors should model around $100m in peak sales for its denosumab biosimilars, pointing to intense pricing pressure and a crowded competitive landscape.
Generics Bulletin - February 16, 2026

From Industry To Regulator And Back: Segan Talks Life After CDRH
Ross “Rusty” Segan discusses his brief tenure as director at the FDA's Office of Product Evaluation and Quality, where he aimed to modernize operations. His current work as a consultant and venture capitalist allows him to leverage his regulatory insights to support medical device innovation.
Medtech Insight - February 16, 2026

Bayer’s Precision Medicine Approach Shows Signs Of Delivering On Growth Strategy
Scrip spoke to global heads of research and early development for oncology, Dominik Ruettinger, and for cardiovascular/renal, Andrea Haegebarth, about Bayer’s strategic focus on precision medicines and key milestones for both therapeutic areas in 2026.
Scrip - February 16, 2026

Roche’s Gazyva Hits Main Goal In Phase III Primary Membranous Nephropathy Trial
Following positive Phase III data, Roche is preparing regulatory filings that could set up a new indication for Gazyva in primary membranous nephropathy, a setting with limited treatment options.
Scrip - February 16, 2026

MHRA Runs CE-Marking Consultation Until April 10
The UK MHRA issued its targeted consultation on the indefinite recognition of CE marked devices in Great Britain on Feb. 16.
Medtech Insight - February 16, 2026

Pipeline Watch: Three Approvals And Two Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - February 16, 2026

Deals Shaping The Industry, January 2026
An interactive look at pharma, medtech and diagnostics deals made during January 2026. Data courtesy of Biomedtracker.
In Vivo - February 16, 2026

‘This Can Be Weaponized’ – Sandoz Sounds Alarm Over Cheap Chinese Antibiotics As India Takes Action
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
Generics Bulletin - February 16, 2026

Over The Counter: ESG, Eco?Pricing and Sustainable Packaging, with Steve Ramus
In the second part of HBW Insight's interview with sustainability expert Steve Ramus, we did deeper into the practicalities of sustainable consumer healthcare, for example how and whether to remove plastics from packaging and if consumers are willing to pay extra for eco-designed products.
HBW Insight - February 16, 2026

BioBytes: BMS Taps Evinova’s AI Platform To Optimize Global Portfolio
Bristol Myers Squibb will deploy Evinova's AI-native platform across its global clinical portfolio to optimize trial design, reduce costs, and accelerate development timelines.
In Vivo - February 16, 2026

Ascletis Progresses Amylin Obesity Pipeline With View To Collaborations
Chinese company expands its amylin-targeting portfolio in obesity with fast-paced plans for progressing clinical trials in the US and finding partners.
Scrip - February 16, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Scrip Asks on R&D Innovation; Bayer’s “paradigm-changing” stroke results; AstraZeneca’s precision oncology approach; Gilead’s CMO reflects on pipeline; and India’s pharma chiefs on driving innovation.
Scrip - February 16, 2026